Doxorubicin for the treatment of hepatocellular carcinoma: GAME OVER!
作者信息
Guiu Boris, Assenat Eric
机构信息
Department of Radiology, St-Eloi University Hospital, Montpellier, France.
Department of Oncology, St-Eloi University Hospital, Montpellier, France.
出版信息
Ann Transl Med. 2020 Dec;8(24):1693. doi: 10.21037/atm-2020-131.
Abstract
摘要
相似文献
1
Doxorubicin for the treatment of hepatocellular carcinoma: GAME OVER!阿霉素用于治疗肝细胞癌：游戏结束！
Ann Transl Med. 2020 Dec;8(24):1693. doi: 10.21037/atm-2020-131.
2
Doxorubicin (75 mg/m2) for hepatocellular carcinoma: clinical and pharmacokinetic results.
Cancer Treat Rep. 1984 Mar;68(3):487-91.
3
MiR-26a-5p Inhibits Cell Proliferation and Enhances Doxorubicin Sensitivity in HCC Cells via Targeting AURKA.miR-26a-5p 通过靶向 AURKA 抑制 HCC 细胞增殖并增强阿霉素敏感性。
Technol Cancer Res Treat. 2019 Jan 1;18:1533033819851833. doi: 10.1177/1533033819851833.
4
Melatonin reverses tunicamycin-induced endoplasmic reticulum stress in human hepatocellular carcinoma cells and improves cytotoxic response to doxorubicin by increasing CHOP and decreasing survivin.褪黑素逆转了衣霉素诱导的人肝癌细胞内质网应激，并通过增加 CHOP 和减少生存素来提高多柔比星的细胞毒性反应。
J Pineal Res. 2013 Sep;55(2):184-94. doi: 10.1111/jpi.12061. Epub 2013 May 25.
5
Uptake of lipiodol-cytotoxics conjugates by hepatocellular carcinoma cells.
J Pediatr Surg. 2004 Feb;39(2):203-6; discussion 203-6. doi: 10.1016/j.jpedsurg.2003.10.011.
6
Polo-like kinase 1 as a promising diagnostic biomarker and potential therapeutic target for hepatocellular carcinoma.Polo样激酶1作为一种有前景的肝细胞癌诊断生物标志物和潜在治疗靶点。
Tumour Biol. 2020 Apr;42(4):1010428320914475. doi: 10.1177/1010428320914475.
7
Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial.多柔比星载纳米粒治疗索拉非尼治疗失败的晚期肝细胞癌患者（RELIVE）：一项 3 期随机对照临床试验。
Lancet Gastroenterol Hepatol. 2019 Jun;4(6):454-465. doi: 10.1016/S2468-1253(19)30040-8. Epub 2019 Apr 4.
8
Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma.多柔比星、α干扰素和大剂量他莫昔芬联合治疗晚期肝细胞癌的II期研究
Hepatogastroenterology. 2004 May-Jun;51(57):815-9.
9
[Transcatheter arterial chemoembolization with doxorubicin eluting beads in the treatment of hepatocellular carcinoma].经动脉化疗栓塞联合阿霉素洗脱微球治疗肝细胞癌
Acta Med Port. 2011 Jan-Feb;24(1):29-36. Epub 2011 Feb 28.
10
Epithelial cell adhesion molecule in human hepatocellular carcinoma cell lines: a target of chemoresistence.人肝癌细胞系中的上皮细胞粘附分子：化疗耐药的一个靶点。
BMC Cancer. 2016 Mar 16;16:228. doi: 10.1186/s12885-016-2252-y.
引用本文的文献
1
Targeting inflammatory pathways in hepatocellular carcinoma: recent developments.肝细胞癌中炎症通路的靶向治疗：最新进展
Discov Oncol. 2025 Jun 22;16(1):1174. doi: 10.1007/s12672-025-03035-8.
2
The role of FOXA1 and miR-212-3p in molecular modulation of doxorubicin resistance in liver cancer.FOXA1和miR-212-3p在肝癌多柔比星耐药分子调控中的作用
Med Oncol. 2025 Apr 11;42(5):160. doi: 10.1007/s12032-025-02686-5.
3
Synergistic impacts of rifampicin and doxorubicin against thioacetamide-induced hepatocellular carcinoma in rats.利福平与阿霉素对硫代乙酰胺诱导的大鼠肝细胞癌的协同作用
Liver Res. 2023 Nov 25;7(4):352-360. doi: 10.1016/j.livres.2023.11.005. eCollection 2023 Dec.
4
Nano-Formulations of Natural Antioxidants for the Treatment of Liver Cancer.天然抗氧化剂的纳米制剂治疗肝癌。
Biomolecules. 2024 Aug 19;14(8):1031. doi: 10.3390/biom14081031.
5
Comprehensive Profiling and Therapeutic Insights into Differentially Expressed Genes in Hepatocellular Carcinoma.肝细胞癌中差异表达基因的综合分析及治疗见解
Cancers (Basel). 2023 Nov 30;15(23):5653. doi: 10.3390/cancers15235653.
6
Drug-Eluting Embolic Loaded with Tyrosine Kinase Inhibitor Targeted Therapies for Transarterial Chemoembolization in a VX2 Model.载有酪氨酸激酶抑制剂的药物洗脱栓塞物用于VX2模型经动脉化疗栓塞的靶向治疗
Cancers (Basel). 2023 Jun 18;15(12):3236. doi: 10.3390/cancers15123236.
7
Tumor Microenvironment of Hepatocellular Carcinoma: Challenges and Opportunities for New Treatment Options.肝细胞癌的肿瘤微环境：新治疗方案面临的挑战与机遇
Int J Mol Sci. 2022 Mar 29;23(7):3778. doi: 10.3390/ijms23073778.
本文引用的文献
1
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌。
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
2
Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial.索拉非尼联合阿霉素与单独使用索拉非尼治疗晚期肝细胞癌的疗效评估：3期CALGB 80802随机临床试验
JAMA Oncol. 2019 Nov 1;5(11):1582-1588. doi: 10.1001/jamaoncol.2019.2792.
3
Idarubicin-loaded Beads for Chemoembolization of Hepatocellular Carcinoma: The IDASPHERE II Single-Arm Phase II Trial.载阿霉素微球化疗栓塞治疗肝细胞癌的二期临床试验：IDASPHERE II 单臂二期试验。
Radiology. 2019 Jun;291(3):801-808. doi: 10.1148/radiol.2019182399. Epub 2019 Apr 30.
4
Sorafenib alone vs. sorafenib plus GEMOX as 1-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial.索拉非尼单药对比索拉非尼联合 GEMOX 方案作为晚期 HCC 一线治疗的随机 II 期 PRODIGE 10 试验。
Br J Cancer. 2019 Apr;120(9):896-902. doi: 10.1038/s41416-019-0443-4. Epub 2019 Apr 4.
5
Current trends in the treatment of hepatocellular carcinoma with transarterial embolization: a cross-sectional survey of techniques.经动脉栓塞治疗肝细胞癌的现状：技术的横断面调查。
Eur Radiol. 2019 Jun;29(6):3287-3295. doi: 10.1007/s00330-018-5782-7. Epub 2018 Oct 22.
6
Intra-arterial idarubicin_lipiodol without embolisation in hepatocellular carcinoma: The LIDA-B phase I trial.动脉内伊达比星-碘油乳剂不栓塞治疗肝细胞癌：LIDA-B 期 I 试验。
J Hepatol. 2018 Jun;68(6):1163-1171. doi: 10.1016/j.jhep.2018.01.022. Epub 2018 Feb 8.
7
Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents.克服ABC转运蛋白介导的多药耐药性：酪氨酸激酶抑制剂作为多靶点药物的双重作用。
Eur J Med Chem. 2017 Dec 15;142:271-289. doi: 10.1016/j.ejmech.2017.07.062. Epub 2017 Aug 3.
8
Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone.多柔比星洗脱微球与单纯微球栓塞治疗肝细胞癌的肝动脉栓塞随机试验
J Clin Oncol. 2016 Jun 10;34(17):2046-53. doi: 10.1200/JCO.2015.64.0821. Epub 2016 Feb 1.
9
Idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase I trial.载阿柔比星微球用于肝癌化疗栓塞术：IDASPHERE Ⅰ期试验结果。
Aliment Pharmacol Ther. 2014 Jun;39(11):1301-13. doi: 10.1111/apt.12746. Epub 2014 Apr 16.
10
Sorafenib overcomes irinotecan resistance in colorectal cancer by inhibiting the ABCG2 drug-efflux pump.索拉非尼通过抑制 ABCG2 药物外排泵克服结直肠癌的伊立替康耐药性。
Mol Cancer Ther. 2013 Oct;12(10):2121-34. doi: 10.1158/1535-7163.MCT-12-0966. Epub 2013 Aug 19.
Zotero 插件